BOULDER, Colo.--(BUSINESS WIRE)--Today, ArcherDX launched Archer™ PreSeq™ QC Assays, which assess the quality of nucleic acid in FFPE samples prior to library creation for next-generation sequencing (NGS)-based mutation detection. “NGS is an extremely effective way to find oncogenic driver mutations in a tumor specimen, but analytical sensitivity and specificity are dependent upon the quality of the sample. PreSeq assays provide users the ability to assess the quality of nucleic acid in a specimen before beginning time-consuming and costly library preparation,” says Josh Stahl, Vice-President of R&D and Scientific Operations at ArcherDX.
Help employers find you! Check out all the jobs and post your resume.
